54 Citazioni (Scopus)


Because the p16 locus is involved consistently in chromosomal losses found in malignant gastrointestinal stromal tumors (GISTs), we studied p16 in a series of 21 GISTs with complete follow-up using immunohistochemical analysis, semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) and methylation-specific PCR (MSP). A fraction of cells of more than 20% with low or absent p16 immunostaining was detected in 12 GISTs, including all showing malignancy. RT-PCR revealed decreased p16 transcription in all except 2 p16 protein-deficient GISTs. By MSP, 7 cases showed p16 promoter methylation (all hypoexpressing p16; 6 malignant). A fraction of p16-deficient cells of more than 20% was associated with clinical malignancy (P = .003; log-rank test). The percentage of cells underexpressing p16, size, cellularity, mitotic count, and coagulative necrosis were associated with malignancy by Cox proportional hazards univariate analysis; only the former factor was selected by multivariate analysis (P = .039). Thus, p16 down-regulation, partly due to p16 promoter methylation, is implied in GIST progression. Furthermore, p16 immunohistochemical assessment seems a promising method for GIST prognostication.
Lingua originaleEnglish
pagine (da-a)35-43
Numero di pagine9
RivistaAmerican Journal of Clinical Pathology
Stato di pubblicazionePubblicato - 2004


  • Aged
  • Aged, 80 and over
  • Cyclin-Dependent Kinase Inhibitor p16
  • DNA Methylation
  • Disease Progression
  • Female
  • Gastrointestinal Neoplasms
  • Humans
  • Immunohistochemistry
  • Male
  • Middle Aged
  • Prognosis
  • Reverse Transcriptase Polymerase Chain Reaction
  • Stromal Cells
  • Tumor Markers, Biological

Fingerprint Entra nei temi di ricerca di 'Role of p16/INK4a in gastrointestinal stromal tumor progression'. Insieme formano una fingerprint unica.

Cita questo